Heptares and Kymab in collaboration to bring new antibodies to market

18 April 2016

Heptares Therapeutics, a subsidiary of Japanese drugmaker Sosei Group (TYO Mothers Index: 4565), has entered into a strategic collaboration with UK-based pharma company Kymab, to develop and market novel antibody therapeutics.

These antibodies will target a number of G protein-coupled receptors (GPCR) with an initial focus on immuno-oncology, activating the body’s immune system to produce an immune response targeted at tumor cells.

Immunotherapy drugs have been hailed as having the potential to revolutionize the way cancer is treated and a number of immunotherapy antibody treatments have recently been approved.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK